Pfizer Inc. $PFE Shares Purchased by KKM Financial LLC

KKM Financial LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 28.9% in the third quarter, HoldingsChannel.com reports. The firm owned 149,996 shares of the biopharmaceutical company’s stock after buying an additional 33,601 shares during the quarter. KKM Financial LLC’s holdings in Pfizer were worth $3,822,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after buying an additional 10,198,330 shares in the last quarter. Norges Bank purchased a new stake in Pfizer in the 2nd quarter worth $2,270,157,000. Fisher Asset Management LLC lifted its holdings in Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after purchasing an additional 897,786 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 2.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after purchasing an additional 1,135,457 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Pfizer by 8.6% during the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after purchasing an additional 3,296,415 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. Barclays began coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target on the stock. Bank of America reduced their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Royal Bank Of Canada started coverage on Pfizer in a research note on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price target on the stock. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $28.05.

Pfizer Price Performance

NYSE:PFE opened at $26.60 on Monday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The stock has a market cap of $151.23 billion, a PE ratio of 19.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The stock has a 50 day moving average price of $26.50 and a 200 day moving average price of $25.53.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the prior year, the business earned $0.63 EPS. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.